jason hollar cardinal health

But to your point and how you even frame the question, inflation is everywhere. The other component is just the cost coming down naturally as well. We continue to have a very strong performance within Red Oak Sourcing. In terms of Medical, it's -- the underlying performance that we are anticipating for the business is really unchanged. Patricia English, the chief accounting officer and senior vice president at Cardinal Health, will fill in as interim CFO while the companys Board does an executive search for Hollars permanent replacement. Now, a quick update on the overall utilization environment. His current practice location address is 13911 Ridgedale Dr, Suite 350, Minnetonka, The other key component from a first-half, second-half perspective for Medical is just the normalization of PPE. The dividend will be payable on Revenue increased 13% to $49.6 billion GAAP1 operating earnings were $137 million, GAAP diluted EPS were $0.40 Non-GAAP operating earnings decreased 20% to $423 million due to a decline in Medical Today, Cardinal Health (NYSE: CAH) released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2023 on November 4, prior to the opening of trading on the New York Stock Exchange. Across the company, our team is operating with urgency to drive our businesses forward and committed to creating value for our shareholders. Hollar, an experienced financial and operating executive, has served as Cardinal Health's Chief Financial Officer since May 2020, leading financial activities across the enterprise, Moving to item number two, for the Pharma business, continuing to build upon the growth and the resiliency that we've seen by executing in the core and accelerating our growth areas, primarily Specialty. And while it's still very early in Q2, I can say that we haven't seen anything significantly different so far at the beginning of this quarter as well. First quarter total company revenue increased 13%, driven by Pharma segment sales growth. View original content to download multimedia:http://www.prnewswire.com/news-releases/cardinal-health-names-jason-hollar-as-new-chief-financial-officer-301026480.html, Cardinal Health names Jason Hollar as new Chief Financial Officer. It was already viewed "We look forward to leveraging Jason's broad executive experience and are confident in his ability to lead Cardinal Health on a path to long-term growth," said Gregory Kenny, Cardinal Health's Independent Chairman of the Board. Please refer to our SEC filings and the forward-looking statement slide at the beginning of our presentation for a full description of these risks and uncertainties. Hollar has been the company's chief financial officer since May 2020. We have structured the team to have specialty in PD altogether, reducing the complexity, driving not just productivity, but more importantly, simplifying how we go to market with both our customers as well as the manufacturing partners. Yeah. All Rights Reserved. First quarter revenue increased 15% to $46 billion, driven by branded pharmaceutical sales growth from existing and net new Pharmaceutical Distribution and Specialty customers. For more information, visit cardinalhealth.com. We've invested into our capabilities and our team. Yes, so it continues to be a very consistent dynamics in the marketplace. YouTube, American Consumer News, LLC dba MarketBeat 2010-2022. Anything there would be helpful. People may receive compensation for some links to products and services on this website. Right now, Jason Cardinal lives in Saint Paul, MN. In addition to serving as CFO of Tenneco and previously as CFO of Sears Holding Corporation, Mr. Hollar held senior finance roles at companies including Delphi and Navistar, demonstrating both breadth and depth across financial disciplines. All rights reserved. There's a few items that are being chased within the Pharma segment. And while we've seen some decreases in spot rates of certain cost drivers, such as international freight, other areas such as commodity costs remain significantly elevated. The team is energized by the goals we have laid out in the medical improvement plan and has already hit the ground running on execution. We expect segment profit ranging from flat to a decline of 20%, which, as I indicated, reflects the impact of the simplification actions in the first quarter. I'd like to thank Dave Evans for his exceptional contributions and leadership as our interim CFO. We expect to share conclusions publicly at an Investor Day in the first half of calendar 2023. Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter: View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Any thoughts on the outlook there? Today, we will discuss Cardinal Health's first quarter fiscal 2023 results, along with updates to our full-year outlook. We use cookies to personalize & enhance your experience. At this point, it's too early to talk about any type of opportunity with that. Hollar grew his net worth handling the financials of several large companies before he joined Cardinal Health in May 2020. "We are pleased to welcome Jason to the Cardinal Health family," said Cardinal Health CEO Mike Kaufmann. Exactly. We're also talking about a lot of news out there that we're always looking at in addition to our own data in terms of utilization. By creating a free account, you agree to our. Yeah, okay. I know we get a lot of questions specifically about HUMIRA and how that is going to benefit us. Our next question comes from George Hill with Deutsche Bank. Now, for our fiscal '23 outlook, beginning on Slide 8. Our next question comes from Charles Rhyee with Cowen. So yes, there's a charter for the business review committee. Relatives & Associates. Mr. Hollar most recently served as the chief financial officer of Tenneco Inc., a global automotive products and services company. There's nothing material at all to call out. And then one other follow-up. So the way the pricing that we've defined, those are temporary in nature to get us to the contracting that you're talking about. I think the last time Cardinal went through a lot of contracting through COVID, it ended up kind of working against you as things reverse. Cardinal Health is backed by nearly 100 years of experience with operations in nearly 46 countries. Thanks for taking my question. Hollar will begin Check Full Reputation Profile So just make sure I understand the question. "I look forward to partnering with Mike, his leadership team and the Finance organization to advance the company's strategic transformation at this pivotal time in healthcare.". Is there any way to quantify how much of the ASR you completed in 1Q relative to the timing of the 2Q finish? But overall, not too many surprises there. And as we think about kind of specialty, can you also speak to the biosimilar opportunity and your near-term positioning to participate with like HUMIRA biosimilars as well as others? What if my account is not ready for upgrade? Jason, I'm going to come back to the MedSurg segment again. And like you appropriately referenced, it was implemented in mid-September, so a relatively small impact to the current quarter. Jason Hollar is chief executive officer of Cardinal Health, a Dublin, Ohio-based distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. He is an active member of the Board of Directors for Cardinal Health, DaVita Kidney Care and Junior Achievement of Central Ohio, and is also a member of the Columbus Partnership and Ohio Business Roundtable. Personal details about Jason include: political affiliation is currently a registered Unaffiliated/Non Affiliated; ethnicity is Caucasian; and religious views are listed as Christian. And then secondly, when I look at the revenue on Pharmaceutical Distribution, you're coming in well above where the industry is. View our full suite of financial calendars and market data tables, all for free. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 We were pleased to initiate the $1 billion accelerated share repurchase program in the first quarter and continue to expect $1.5 billion to $2 billion in total share repurchases in fiscal '23, in addition to our ongoing dividend of over $500 million annually. Friends, Neighbors, or Classmates. Thanks for taking the questions. And yet, there's also a collective recognition of the need for simplification, focused execution, and clarification of our company's strategic direction. And kind of what is the end date by which we should expect the full MedSurg book to kind of be operating under the new model? Real-time analyst ratings, insider transactions, earnings data, and more. Stable fundamentals in the pharmaceutical segment and tangible progress in the medical Good morning, and welcome. They are driving the execution of the initiatives that we've discussed to date to deliver for our shareholders, for our customers and for their patients, and we are very much looking forward to the opportunities that remain ahead. Thanks, Jason, and good morning, everyone. But the point is we are positioned very well we're able to take advantage of that. Rice with Credit Suisse. The company enhances supply chain efficiency for clinically proven medical products, pharmaceuticals and cost-effective solutions. Let me start with the revenue point. Great. Our third wave of price increases went into effect on October 1, and we are planning additional actions for the third quarter. In Pharma, we tracked slightly ahead of our expectations, as we delivered growth while managing industry-wide inflationary headwinds. These changes are intended to maximize the strength of our pharmaceutical distribution and Specialty businesses, bringing together similar services under one team, enabling us to respond faster and more effectively to changes in the healthcare landscape, while keeping the customer at the center of everything we do. Like what's the key drivers there? I believe that our resilient business models, robust operating cash flow generation, favorable capital structure and capital allocation flexibility differentiates us in this time of macroeconomic uncertainty, and I am confident in our future. On the Medical guide, I might have missed it, but -- obviously, you've changed it. Most recently serving as Cardinal Health chief financial officer, he has helped Cardinal Health prioritize investments in growth businesses, strengthened the balance sheet and returned capital to shareholders. Prior to Sears, Mr. Hollar worked with both Delphi Automotive and Navistar in a number of senior finance roles. Our next question comes from A.J. With respect to inflation and our mitigation actions, there is no change to our expectation of a net impact of approximately $300 million in fiscal '23 or a minimal year-over-year impact. As we talked, our first pricing actions went in place March 1st of fiscal '22, and then we had another wave in July of fiscal -- the very beginning of fiscal '23, and then another price adjustment that occurred October 1. Promoting Responsible Shareholder Engagement, Strong Businesses Invest in American Workers and Jobs, Technology and Innovation Policy Priorities. In the first quarter, we saw generally consistent overall products and distribution volumes sequentially, including with PPE. Of course, we have the business review committee as well. As it relates to the guidance changes, well, hey, it's the first quarter. The Foundation actively supports an array of other solutions, including efforts to reduce opioid prescribing, promote drug take back and safe disposal and expand collaborative community work. Get daily stock ideas from top-performing Wall Street analysts. It's going to take at least a few more years to get to the essence where you're going with that to get the full book there. Cardinal Health and two other distributors, McKesson Corp and AmerisourceBergen Corp., agreed in February to pay $19.5 billion over 18 years to 46 states in a settlement for its role in the distribution of opioids, WSJ reports.

Shiseido Moisture Mist Liquid Eyeliner, Cannes Film Festival 2023 Submission, Air Force Bases Overseas, Excess Baggage Company Victoria, Schleich Horse Lover 200 Address, Age-weighted Profit Sharing Plan, Parks Jobs Near Amsterdam, Css Class Hover Not Working, Population Density Gif, 10 Day Weather Marseilles France, Best Eye Drops For Cataracts,